Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT in BRCA1-associated breast cancer patients

详细信息    查看全文

• 作者：Grigorijs Plakhins (1)
  Arvids Irmejs (1)
  Andris Gardovskis (1)
  Signe Subatniece (1)
  Inta Liepniece-Karele (2)
  Gunta Purkalne (1)
  Uldis Teibe (3)
  Genadijs Trofimovics (1)
  Edvins Miklasevics (1)
  Janis Gardovskis (1)
  
• 关键词：BRCA1 ; Founder mutations ; Breast cancer ; Adjuvant chemotherapy
• 刊名：Familial Cancer
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：12
• 期：4
• 页码：683-689
• 全文大小：
• 作者单位：Grigorijs Plakhins (1)
  Arvids Irmejs (1)
  Andris Gardovskis (1)
  Signe Subatniece (1)
  Inta Liepniece-Karele (2)
  Gunta Purkalne (1)
  Uldis Teibe (3)
  Genadijs Trofimovics (1)
  Edvins Miklasevics (1)
  Janis Gardovskis (1)
  
  1. Oncology Institute, Riga Stradins University, Pilsou Street 13, Riga, 1002, Latvia
  2. Pathology Center, Riga East Clinical University hospital, Hipokrata street 2, Riga, LV-1038, Latvia
  3. Department of Physics, Riga Stradins University, Dzirciema street 16, Riga, LV-1007, Latvia
  
• ISSN：1573-7292

文摘

BRCA1-associated breast cancer is considered an unique clinical entity with its own specific histopathological characteristics. Several recently published large studies have shown that overall survival of BRCA1 mutation carriers having breast cancer is similar to sporadic breast cancer patients. It was also suggested that better response to chemotherapy is one of the most important factors that improves the clinical outcome of breast cancers with unfavorable histopathological subtypes in BRCA1 mutation carriers. Adjuvant! Online and PREDICT are web-based prognostic tools that estimate the survival benefit of adjuvant chemotherapy in primary breast cancer patients. These tools have been extensively validated in different populations; however, the accuracy of the predictions made by Adjuvant! Online and PREDICT among BRCA1 mutation carriers has not yet been investigated. In this study we have found, that predictions of overall and breast cancer-specific survival obtained from Adjuvant! Online and PREDICT were significantly lower than the observed survival percentages in the study population [predictedbserved difference for 10ear overall survival: 9.75%, P<0.0001 (Adjuvant! Online); 10.21%, P<0.0001 (PREDICT)]. Thus this study suggests that Adjuvant! Online and PREDICT should be used with caution in this group of patients. Further updating of adjuvant therapy benefit calculation tools by inclusion of the information about inherited genetic alterations should be considered to improve the performance of the prognostic programs among hereditary breast cancer patients.